At the University of Colorado Anschutz, researchers have found something that could reshape how women with polyendocrine metabolic ovarian syndrome approach their health: a single injectable medication that tackles both fertility and metabolic problems at once.
For years, women with PMOS—formerly known as polycystic ovary syndrome—have faced an impossible choice. Medications like metformin and hormonal contraceptives can help manage irregular periods and elevated testosterone, but they don't adequately address the obesity and metabolic dysfunction that so often accompany the condition. Meanwhile, treatments targeting metabolic health rarely improve reproductive outcomes. This gap in care has left many women unable to find a single therapy that addresses their whole health picture.
Now, a proof-of-concept study published in Fertility and Sterility by researcher Melanie Cree, MD, Ph.D., a pediatric endocrinologist at Children's Hospital Colorado, suggests that injectable semaglutide—a medication better known for weight loss—may offer something different. The analysis, drawn from the ongoing CU Anschutz-led RESTORE clinical trial, examined participants ages 12 to 35 who achieved at least 10 percent body weight loss during treatment. What surprised the research team was how quickly reproductive improvements appeared. Reproductive health markers improved so rapidly and meaningfully that investigators decided to publish preliminary findings while the larger study continues.
"Women with PMOS frequently face a frustrating choice between treatments that target reproductive symptoms and those that address metabolic health," Cree explained. "Our early findings suggest injectable semaglutide may have the potential to improve both, offering a more comprehensive approach to care."
PMOS is genuinely complex. It combines irregular menstrual cycles, elevated testosterone, infertility risk, and heightened rates of obesity and cardiometabolic disease—a constellation of problems that no single existing therapy has adequately solved. Semaglutide, a GLP-1 medication, works by helping people lose weight and improve metabolic function. But the critical question has always been: what does that weight loss actually do for fertility in women specifically dealing with PMOS? Until now, that question remained largely unanswered by rigorous research.
The RESTORE trial is still enrolling and following girls and women with PMOS and obesity to determine whether weight loss and metabolic improvements can restore ovulation and enhance reproductive outcomes. The team's observation that reproductive benefits emerged earlier than expected during the study suggests the medication may work through multiple pathways—not just through weight loss alone, though Cree noted that "this medication is incredibly promising when someone responds with 10% weight loss."
The researchers are careful not to overstate their findings. This is early work, proof-of-concept rather than definitive proof. The team acknowledges that larger, longer-term studies will be needed to confirm whether reproductive benefits last over time and to understand exactly how semaglutide produces these improvements. But for women with PMOS who are juggling competing health concerns, the promise is real. Here, at last, may be a single therapy that doesn't force them to choose between fertility and metabolic health.